Adisa Kuburas

Adisa Kuburas

Auto-generated profile, based on publicly available information

Adisa Kuburas

Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2025 in Cephalalgia
Verified
Journal Article
Open access
EZErik Zorrilla
Erik Zorrilla
GKGeorgii Krivoshein
Georgii Krivoshein
AKAdisa Kuburas
Adisa Kuburas
MSMaarten Schenke
Maarten Schenke
CPCassandra L. Piña
Cassandra L. Piña
AWAnne-Sophie Wattiez
Anne-Sophie Wattiez
Background: The therapeutic use of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to treat migraine has been understudied. Using three mouse models, we examined the impact of CBD and THC on migraine-relevant behaviors triggered by: 1) calcitonin gene-related peptide (CGRP), 2) sodium nitroprusside (SNP), and 3) cortical spreading depolarization (CSD). Methods: Both male and female CD1 mice were treated with CBD (100 mg/kg) or THC (1 mg/kg) alone or in combinations of CBD (1, 30 or 100 mg/kg) and THC (1 mg/kg) prior to injection of CGRP or SNP. The mice were assessed for light aversion (photophobia), squint (non-evoked pain), and periorbital tactile hypersensitivity, as well as possible adverse effects. In a separate set of experiments, CSD events were optogenetically induced in familial hemiplegic migraine 1 (FHM1) mutant and wildtype littermates (WT) mice (C57BL/6 background), followed by grimace and motor assessments with and without combinations of CBD (30 or 100 mg/kg) and THC (1 mg/kg). Results: In CD1 mice, a 100:1 CBD:THC combination mitigated light aversion induced by CGRP and SNP in males and females. Rescue of CGRP- and SNP-induced squint was observed only in male mice with 100:1 CBD:THC. None of the treatments rescued periorbital tactile hypersensitivity in either sex. In FHM1 mutant and WT mice, the 100:1 CBD:THC ratio did not affect CSD characteristics but did reduce CSD-induced grimace features (i.e., head pain mimic). No adverse effects of any of the cannabinoid treatments were observed using cognitive, emotional, or motor tests. Conclusions: A 100:1 ratio of CBD:THC has a beneficial effect on some of the most bothersome migraine-related symptoms in three mouse models. Our findings support a potential therapeutic efficacy of combined CBD and THC treatments.

11 September 2025 in Cephalalgia
Verified
Journal Article
Open access
APAdriana Della Pietra
Adriana Della Pietra
AKAdisa Kuburas
Adisa Kuburas
ARAndrew F. Russo
Andrew F. Russo
Migraine is a complex neurological disorder involving multiple neuropeptides that modulate nociceptive and sensory pathways. The most studied peptide is calcitonin gene-related peptide (CGRP), which is a well-established migraine trigger and therapeutic target. Recently, another peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), has emerged as an alternative target for migraine therapeutics. This review compares the roles of PACAP and CGRP in preclinical mouse models of migraine. PACAP shares similarities with CGRP, and both are expressed in peripheral and central migraine-relevant regions. However, CGRP is more abundant in the trigeminal pain system, whereas PACAP is more prominent in parasympathetic ganglia that may contribute to autonomic aspects of migraine. PACAP and CGRP act on receptors that can activate overlapping but distinct intracellular signaling pathways. While both peptides elevate cAMP levels to activate protein kinase A, PACAP is more effective than CGRP at engaging an alternative cAMP pathway involving small G proteins, as well as Gq-mediated calcium pathways. Moreover, PACAP and CGRP induce similar migraine-like behaviors in mice, including cephalic and plantar mechanical allodynia, photophobia and non-evoked pain, but they do so by largely independent pathways. Notably, PACAP-mediated photophobia and mechanical allodynia symptoms are not blocked by CGRP-targeted therapies in mice. Finally, we discuss how preclinical PACAP and CGRP studies have translated to the clinic, with the exception of a PACAP type I receptor monoclonal antibody. Overall, CGRP and PACAP are likely to act by parallel and non-redundant roles in migraine pathophysiology, which suggests that a combined targeting of CGRP and PACAP may offer a more effective strategy for treating migraine.

13 November 2026 in British Journal of Pharmacology
Verified
Journal Article
Open access
JWJayme S. Waite
Jayme S. Waite
AKAdisa Kuburas
Adisa Kuburas
QHQuinn K. Hanigan
Quinn K. Hanigan
JTJamie L. Thoma
Jamie L. Thoma
BRBrandon J. Rea
Brandon J. Rea
ARAndrew F. Russo
Andrew F. Russo
Background and Purpose: The neuropeptide calcitonin gene‐related peptide (CGRP) is a well‐established player in migraine. Current CGRP migraine therapeutics were designed to inhibit the canonical CGRP receptor, yet, based on in vitro studies, they can also inhibit to a lesser degree the amylin receptor 1 (AMY 1 ), which CGRP can also activate. This study explores the potential in vivo contributions of these receptors to migraine‐like symptoms in mice. Experimental Approach: Receptor contributions were probed using light aversion as a surrogate for photophobia and diarrhoea as a readout for gastrointestinal dysfunction in outbred CD1 mice. Induction of diarrhoea was also measured in C57BL/6 J mice. CGRP and amylin were used as agonists, with two selective antagonists, olcegepant for the canonical CGRP receptor and AC187 for calcitonin receptor (CT)‐based receptors, including AMY 1 . Key Results: CGRP and amylin induced light aversion in CD1 mice and diarrhoea in both strains. CGRP‐induced light aversion was partially rescued by AC187, but not olcegepant. Light aversion was fully rescued only by a combination of AC187 and olcegepant. In contrast, olcegepant fully blocked CGRP‐induced diarrhoea, while AC187 only partially blocked at high doses. As a control, olcegepant fully rescued CGRP‐induced periorbital touch hypersensitivity in CD1 mice. Conclusions and Implications: More than one receptor contributes to CGRP‐induced light aversion, with a CT‐based receptor unexpectedly playing a major role. In contrast, the canonical CGRP receptor plays a major role in CGRP‐induced diarrhoea. Thus, targeting a CT‐based receptor may reduce photophobia with less adverse gastrointestinal effects in migraine patients.